Search

Displaying results 1381 - 1390 of 5384 in total
  1. Drug

    Hypromellose

    go.drugbank.com/drugs/DB11075
    ApprovedInvestigational

    Hypromellose, or hydroxypropyl methylcellulose (HPMC) , is a semisynthetic, inert, and viscoelastic polymer that forms a colloid solution when dissolved in water. It acts as a thickening agent, coating polymer, bioadhesive, solubility en...

  2. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A18262] Use of non-stimulant medications such as atomoxetine is therefore thought to offer a clinical advantage over the use of traditional medications for the management of ADHD. … [A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum.

  3. Drug

    Tedizolid phosphate

    go.drugbank.com/drugs/DB09042
    Approved

    [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

  4. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat is marketed by Novartis under the brand name Farydak. … Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.

  5. Drug

    Posaconazole

    go.drugbank.com/drugs/DB01263
    ApprovedInvestigationalVet approved

    Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]

  7. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after … Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD.

  8. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.

  9. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    Xylitol is a non-fermentable sugar alcohol by most plaque bacteria, indicating that it cannot be fermented into cariogenic acid end-products [A32423]. … It works by inhibiting the growth of the microorganisms present in plaque and saliva after it accummulates intracellularly into the microorganism [A32423].

  10. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use